

Truncated Militarione Fragments Identified by Total Chemical Synthesis Induce Neurite Outgrowth

Fabian Schmid,^a Henning J. Jessen,^{a,b} Patrick Burch^a and Karl Gademann^a

^a University of Basel, Department of Chemistry, St. Johannis-Ring 19, 4056 Basel, Switzerland, +41 61 267 11 44, karl.gademann@unibas.ch

^b Present address: University of Zurich, Institute of Organic Chemistry, Winterthurerstrasse 190, 8057 Zürich, Switzerland.

Supporting Information

1. General Methods and Materials	2
2. Experimental Procedures	5
3. Experimental Procedure of the PC-12 Assay	35
4. X-Ray Structure Parameters	36
5. NMR Spectra	39
6. HPLC Traces	96

Experimental Part

1. General Methods and Materials

Reactions involving air or moisture sensitive reagents or intermediates were performed under argon or nitrogen in glassware which had been oven dried, heat gun dried or flame dried *in vacuo*. Concentration under reduced pressure was performed by rotary evaporation at 40 °C (unless otherwise specified). Yields refer to purified, dried and spectroscopically pure compounds.

Reagents were purchased from Sigma-Aldrich, ABCR, Acros or Lancaster and used without further purification unless stated otherwise.

Solvents for work-up and chromatography were distilled from technical quality. Solvents used for chemical transformations were either puriss. quality or dried by filtration through activated aluminium oxide under argon or nitrogen (H₂O content < 10 ppm, *Karl-Fischer* titration) in a PureSolve MD 5 solvent purification system.

Thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 plates (0.25 mm thickness) precoated with fluorescent indicator. The developed plates were examined under UV light and stained with potassium permanganate followed by heating.

Flash chromatography was performed using silica gel 60 (230-240 mesh) from Fluka at 0.3-0.5 bar pressure.

¹H and ¹³C NMR spectra were recorded either using Bruker Avance 400 MHz, Bruker Avance DRX 500 MHz, Varian Gemini 300 MHz or Bruker DPX 400 MHz or Bruker DRX 600 MHz spectrometers at room temperature. Chemical shifts (δ-values) are reported in ppm, spectra were calibrated related to the solvent residual proton chemical shift and the solvent residual carbon chemical shift,¹ multiplicity is reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or unresolved and coupling constant *J* in Hz.

¹ H. E. Gottlieb, V. Kotlyar, A. Nudelman, *J. Org. Chem.* **1997**, 62, 7512-7515.

IR spectra were recorded using a *Varian 800 FT-IR ATR Spectrometer*. The absorptions are reported in cm^{-1} .

HRMS-ESI were recorded by the Mass spectrometric Service of the University of Bern on Sciex QSTAR Pulsar mass spectrometer or by the Mass spectroscopy Service of EPF Lausanne on MICROMASS (ESI) Q-TOF Ultima API. Fragment ions are given in m/z using electrospray ionization.

X-ray analyses were performed at low temperature (exact temperature in appendix) using $\text{Mo } K_{\alpha}$ radiation on a Bruker KappaAPEX diffractometer. Integration of the frames and data reduction was carried out using APEX2.² The structures were solved by direct methods using SIR92.³ All non hydrogen atoms were refined by full-matrix least-squares on F using CRYSTALS.⁴ Hydrogen atoms were placed in calculated positions by means of the “riding” model.

Melting points (M.p.) were determined using a Büchi B-545 apparatus in open capillaries and are uncorrected.

Analytical High Performance Liquid Chromatography (HPLC) was performed on a *Dionex Chromatography System* (Interface Chromeleon, ASI 100 automatic sample injector, PDA 100 (USB) PD detector, pump P680, degaser, MSQ-ESI mass spectrometric detector). The flow rate was 1 mL/min and a Phenomenex Gemini 5 μm C18 110A column (250 x 4.6 mm) or a Phenomenex Gemini 5 μm C18 110A column (50 x 4.6 mm) was used.

Semi Preparative High Performance Liquid Chromatography (SP-HPLC) was performed on a *Dionex Chromatography System* (Interface Chromeleon, ASI 100 automatic sample injector, PDA 100 (USB) PD detector, pump P680). The flow rate was 5 mL/min and a Phenomenex Gemini 5 μm C18 110A column (150 x 10 mm) was used.

² Bruker Analytical X-ray Systems, Inc., **2006**. *Apex2*, Version 2 User Manual, M86-E01078, Madison, WI.

³ A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M. C. Burla, G. Polidori, M. Camalli, *J. Appl. Cryst.* **1994**, 27, 435.

⁴ P. W. Betteridge, J. R. Carruthers, R. I. Cooper, K. Prout, D. J. Watkin, *J. Appl. Cryst.* **2003**, 36, 1487.

Lyophilisations were performed with a *Christ Freeze Dryer Alpha 1-2 LD plus*.

2. Experimental procedures


2.1 General Procedure for Suzuki Coupling Reactions

A suspension of ethyl 5-bromo-4-methoxy-2-((2-(trimethylsilyl)ethoxy)methoxy)nicotinate **7**^[5] (1.0 eq.) or ethyl 5-bromo-4-methoxy-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydropyridine-3-carboxylate **8**^[5] (1.0 eq.), Pd(PPh₃)₄ (0.1 eq.), K₂CO₃ (3.0 eq.) and boronic acid derivative (1.5 eq.) in degassed (freeze/thaw) DME/H₂O/DMF (9:1:0.5, 1 mL/100 mg 5-bromo-pyridine substrate) was stirred at 60°C under an argon atmosphere. The reaction was monitored by TLC and diluted with EtOAc upon completion. The organic layer was washed with sat. aq. NH₄Cl, brine (2x) and water (1x), dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude product was purified by gradient flash chromatography and dried *in vacuo*.


⁵ H. J. Jessen, A. Schumacher, T. Shaw, A. Pfaltz, K. Gademann, *Angew. Chem. Int. Ed.* **2011**, 50, 4222.

Ethyl 4-methoxy-5-(4-((4-methoxybenzyl)oxy)phenyl)-2-((2-(trimethylsilyl)ethoxy)methoxy) nicotinate 10^[5]: The compound was prepared

according to literature procedures. All analytical data were in full agreement with previously published values.^[5]




Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydropyridine-3-carboxylate 8a:



The reaction was carried out according to general procedure 2.1. using the following amounts: **8**^[5] (428 mg, 1.1 mmol, 1.0 eq.), Pd(PPh₃)₄ (122 mg, 0.11 mmol, 0.1 eq.), K₂CO₃ (437 mg, 3.3 mmol, 3.0 eq.), 4-methoxyphenylboronic acid (240 mg, 1.6 mmol, 1.5 eq.). The crude material was purified by flash chromatography (SiO₂, pentane/EtOAc 1:1) to give the product **8c** as a yellow oil (418 mg, 0.97 mmol, 92%). *R*_f = 0.17 (SiO₂, pentane/Et₂O, 2:1). **FTIR** (neat): $\tilde{\nu}$ = 2954, 2361, 1730, 1653, 1514, 1463, 1392, 1306, 1248, 1207, 1137, 1086, 835, 632 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 7.33 (s, 1H), 7.30 – 7.27 (m, 2H), 6.96 – 6.90 (m, 2H), 5.33 (s, 2H), 4.41 (q, *J* = 7.1 Hz, 2H), 3.84 (s, 3H), 3.74 (s, 3H), 3.71 – 3.62 (m, 2H), 1.39 (t, *J* = 7.1 Hz, 3H), 1.00 – 0.90 (m, 2H), -0.00 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 166.1, 163.8, 161.3, 159.5, 135.9, 130.3, 126.2, 116.7, 114.1, 112.1, 76.3, 67.6, 62.1, 59.4, 55.5, 18.2, 14.3, -1.2. **HRMS-ESI** calcd for C₂₂H₃₆NO₆Si⁺: 343.1993, found 343.1983.

Ethyl-4-methoxy-5-(4-*N*-Boc-phenyl)-2-((2-(trimethylsilyl)ethoxy)methoxy)-


nicotinate 8b: The reaction was carried out according to general procedure 2.1. using



the following amounts: **7**⁽⁵⁾ (400 mg, 984 μ mol, 1.0 eq.), Pd(PPh₃)₄ (114 mg, 98.4 μ mol, 0.1 eq.), K₂CO₃ (408 mg, 2.95 mmol, 3.0 eq.), *tert*-butyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (471 mg, 1.48 mmol, 1.5 eq.). The crude material was purified by flash chromatography (SiO₂, pentane/Et₂O 2:1 + 0.25% TEA) and was obtained as a yellow oil (510 mg, 983 μ mol, quant.). *R*_f = 0.40 (SiO₂, pentane/Et₂O, 2:1). **FTIR** (neat): $\tilde{\nu}$ = 3342, 2954, 1728, 1590, 1526, 1496, 1443, 1400, 1365, 1319, 1231, 1156, 1076, 1050, 913, 836, 652 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 8.08 (s, 1H), 7.50-7.35 (m, 4H), 6.62 (s, 1H), 5.60 (s, 2H), 4.50-4.30 (m, 2H), 3.75-3.85 (m, 2H), 3.59 (s, 3H), 1.52 (s, 9H), 1.46-1.35(m, 3H), 1.05-0.96 (m, 2H), 0.02 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.5, 163.3, 159.8, 152.8, 149.2, 138.2, 129.7, 129.3, 124.4, 118.7, 110.9, 90.6, 80.9, 67.3, 61.8, 60.7, 28.5, 18.1, 14.4, -1.3. **HRMS-ESI** calcd for C₂₆H₃₉N₂O₆Si⁺: 519.2521, found 519.2505.

Ethyl-4-methoxy-5-(4-*tert*-butylphenyl)-2-((2-(trimethylsilyl)ethoxy)methoxy)

nicotinate 8c: The reaction was carried out according general to general procedure




2.1. using the following amounts: **7⁽⁵⁾** (150 mg, 369 μ mol, 1.0 eq.), Pd(PPh₃)₄ (42.7 mg, 36.9 μ mol, 0.1 eq.), K₂CO₃ (153 mg, 1.11 mmol, 3.0 eq.), 4-*tert*-Butylphenylboronic acid (98.6 mg, 554 μ mol, 1.5 eq.). The crude material was

purified by flash chromatography (SiO₂, pentane/Et₂O 5:1 + 0.20% TEA) and the product was obtained as a yellow oil (88.6 mg, 193 μ mol, 53%). **R_f** = 0.44 (SiO₂, pentane/Et₂O, 5:1). **FTIR** (neat): $\tilde{\nu}$ = 2955, 2925, 1734, 1590, 1468, 1443, 1364, 1322, 1206, 1074, 914, 836, 656, 624 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 8.11 (s, 1H), 7.46-7.36 (m, 4H), 5.62 (s, 2H), 4.43 (q, *J* = 7.2 Hz, 2H), 3.83-3.77 (m, 2H), 3.60 (s, 3H), 1.40 (t, *J* = 7.2 Hz, 3H), 1.36 (s, 9H), 1.04 - 0.96 (m, 2H), 0.01 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.6, 163.3, 159.7, 150.8, 149.3, 131.8, 128.7, 125.6, 124.6, 110.7, 90.6, 67.3, 61.7, 60.7, 34.7, 31.4, 18.1, 14.3, -1.3. **HRMS-ESI** calcd for C₂₅H₃₈NO₅Si⁺: 460.2514, found 460.2500.

Ethyl-4-methoxy-5-(4-fluorophenyl)-2-((2-(trimethylsilyl)ethoxy)methoxy)


nicotinate 8d: The reaction was carried out according general to general procedure

2.1. using the following amounts: **7**⁽⁵⁾ (150 mg, 369 μ mol, 1.0 eq.), Pd(PPh₃)₄ (42.7 mg, 36.9 μ mol, 0.1 eq.), K₂CO₃ (153 mg, 1.11 mmol, 3.0 eq.), 4-fluorophenylboronic acid (77.5 mg, 554 μ mol, 1.5 eq.). The crude material was purified by flash chromatography (SiO₂, pentane/Et₂O 4:1 +0.25% TEA) and the product was obtained as a yellow oil (40.1 mg, 94.9 μ mol, 26%). *R*_f = 0.42 (SiO₂, pentane/Et₂O, 4:1). FTIR (neat): $\tilde{\nu}$ = 2923, 2852, 1718, 1591, 1468, 1442, 1325, 1248, 1217, 1117, 1049, 978, 913, 841, 757, 695, 647 cm⁻¹. ¹H-NMR (400 MHz, CDCl₃) δ = 8.07 (s, 1H), 7.46 - 7.39 (m, 2H), 7.16 - 7.08 (m, 2H), 5.61 (s, 2H), 4.42 (q, *J* = 7.1 Hz, 2H), 3.84 - 3.72 (m, 2H), 3.59 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H), 1.20-0.92 (m, 2H), 0.01 (s, 9H). ¹³C-NMR (101 MHz, CDCl₃) δ = 165.4, 163.8, 162.6 (d, *J* = 247.3 Hz), 161.4, 149.1, 130.8 (d, *J* = 8.1 Hz), 123.9, 115.7 (d, *J* = 21.5 Hz), 110.7, 90.7, 67.4, 61.9, 60.7, 29.8, 18.2, 14.4, -1.4. ¹⁹F-NMR (367 MHz, CDCl₃) δ = -114.6. **HRMS-ESI** calcd for C₂₁H₂₉FNO₅Si⁺: 422.1749, found 429.1788.




Ethyl-4-methoxy-5-(phenyl)-2-((2-(trimethylsilyl)ethoxy)methoxy) nicotinate 8e:

The reaction was carried out according general to general procedure 2.1. using the following amounts: **7**⁽⁵⁾ (100 mg, 246 μ mol, 1.0 eq.), Pd(PPh₃)₄ (28.4 mg, 24.6 μ mol, 0.1 eq.), K₂CO₃ (102 mg, 738 μ mol, 3.0 eq.), phenylboronic acid (45.0 mg, 369 μ mol, 1.5 eq.). The crude material was purified by flash chromatography (SiO₂, pentane/Et₂O 3:1 +0.25% TEA) and the product was obtained as a yellow oil (91.0 mg, 225 μ mol, 92%). **R_f** = 0.56 (SiO₂, Pentane/Et₂O, 3:1). FTIR (neat): $\tilde{\nu}$ = 2992, 2852, 1733, 1589, 1444, 1365, 1321, 1264, 1206, 1060, 983, 912, 835, 700 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 8.11 (s, 1H), 7.53 - 7.30 (m, 5H), 5.62 (s, 2H), 4.43 (q, *J* = 7.2 Hz, 2H), 3.88 - 3.73 (m, 2H), 3.57 (s, 3H), 1.1 (t, *J* = 7.2 Hz, 3H), 1.03-0.96 (m, 2H), 0.01 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.4, 163.3, 159.9, 149.3, 134.8, 129.1, 128.7, 127.8, 124.7, 110.7, 90.6, 67.3, 61.8, 60.7, 18.1, 14.3, -1.4. **HRMS-ESI** calcd for C₂₁H₃₀NO₅Si⁺: 404.1888, found 404.1882.




Ethyl-4-methoxy-5-(3-pyridine)-2-((2-(trimethylsilyl)ethoxy)methoxy) nicotinate



8f: The reaction was carried out according general to general procedure 2.1. using the following amounts: **7**⁽⁵⁾ (150 mg, 369 μ mol, 1.0 eq.), Pd(PPh₃)₄ (42.7 mg, 36.9 μ mol, 0.1 eq.), K₂CO₃ (153 mg, 1.11 mmol, 3.0 eq.), pyridine-3-boronic acid (68.1 mg, 554 μ mol, 1.5 eq.). The crude material was purified by flash chromatography (SiO₂, Et₂O +0.25% TEA) and the product was obtained as a yellow oil (98.7 mg, 244 μ mol, 66%). *R*_f = 0.38 (SiO₂, Et₂O). **FTIR** (neat): $\tilde{\nu}$ = 2920, 2852, 1732, 1586, 1443, 1365, 1266, 1199, 1116, 1065, 993, 910, 836, 714, 666, 627 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 8.70-8.67 (m, 1H), 8.57 (dd, *J* = 4.8 Hz, *J* = 1.9 Hz, 1H), 8.07 (s, 1H), 7.80-7.73 (m, 1H), 7.32 (dd, *J* = 7.9 Hz, *J* = 1.9 Hz, 1H), 5.59 (s, 2H) 4.40 (q, *J* = 7.1 Hz, 2H), 3.81-3.73 (m, 2H), 3.64 (s, 3H), 1.37 (t, *J* = 7.1 Hz, 3H), 0.98-0.93 (m, 2H), -0.02 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.3, 163.0, 160.7, 149.7, 148.9, 148.8, 136.4, 130.6, 123.4, 121.3, 110.1, 90.7, 67.4, 61.9, 60.5, 18.1, 14.1, -1.4. **HRMS-ESI** calcd for C₂₀H₂₉N₂O₅Si⁺: 405.1840, found 405.1833.


Ethyl-5-(4-hydroxy-3-methoxyphenyl)-4-methoxy-2-oxo-1-((2-(trimethylsilyl)



ethoxy) methyl)-1,2-dihydropyridine-3-carboxylate

8g: The reaction was carried out according general to general procedure 2.1. using the following amounts: **8**⁽⁵⁾ (400 mg, 984 μ mol, 1.0 eq.), Pd(PPh₃)₄ (114 mg, 98.4 μ mol, 0.1 eq.), K₂CO₃ (408 mg, 2.95 mmol, 3.0 eq.), 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (369 mg, 1.48 mmol, 1.5 eq.). The crude material was purified by gradient flash chromatography (SiO₂, pentane/Et₂O 1:3 to 0:3 +0.25% TEA) and the product was obtained as a yellow oil (352 mg, 783 μ mol, 80%). *R_f* = 0.38 (SiO₂, Pentane/Et₂O, 1:3). **FTIR** (neat): $\tilde{\nu}$ = 3411, 2953, 1729, 1650, 1515, 1463, 1373, 1246, 1200, 1134, 1084, 1028, 853, 630 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 7.34 (s, 1H), 6.93 (d, *J* = 8.1 Hz, 1H), 6.88 (d, *J* = 1.9 Hz, 1H), 6.83 (dd, *J* = 8.1 Hz, *J* = 1.9 Hz, 1H), 5.78 (s, 1H), 5.33 (s, 2H), 4.41 (q, *J* = 7.1 Hz, 2H), 3.89 (s, 3H), 3.73 (s, 3H), 3.70 - 3.62 (m, 2H), 1.39 (t, *J* = 7.1 Hz, 3H), 0.97-0.91 (m, 2H), 0.00 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 166.0, 163.9, 161.1, 146.6, 145.7, 136.1, 125.8, 122.1, 117.0, 114.6, 111.9, 67.7, 62.1, 59.5, 56.2, 29.8, 25.0, 18.1, 14.3, -1.3. **HRMS-ESI** calcd for C₂₂H₃₄NO₆Si⁺: 450.1943, found 450.1930.


Ethyl-4-methoxy-5- (4-pyridine) -2-oxo-1-((2-(trimethylsilyl) ethoxy)methyl)-1,2-dihydropyridine- 3-carboxylate 8h: The reaction was carried out according



general to general procedure 2.1. using the following amounts: **8⁽⁵⁾** (400 mg, 984 μmol , 1.0 eq.), $\text{Pd(PPh}_3)_4$ (114 mg, 98.4 μmol , 0.1 eq.), K_2CO_3 (408 mg, 2.95 mmol, 3.0 eq.), pyridine-4-boronic acid (181 mg, 1.48 mmol, 1.5 eq.). The organic

layer was extracted with sat. aq. sodium carbonate solution and the crude material was purified by flash chromatography (SiO_2 , DCM/MeOH 25:1 +0.25% TEA) and HPLC (RP18, $\text{H}_2\text{O}/\text{ACN}$ 4:1 to 0:1 in 25 min, 5 mL/min, retention time 3.8 min) and then lyophilised to give a yellow oil (136 mg, 336 μmol , 34%). R_f = 0.14 (SiO_2 , DCM/MeOH 25:1 +0.25% TEA). **FTIR** (neat): $\tilde{\nu}$ = 2954, 2897, 1728, 1650, 1592, 1547, 1463, 1393, 1337, 1306, 1206, 1137, 1084, 1021, 832, 610 cm^{-1} . **¹H-NMR** (400 MHz, CDCl_3) δ = 8.47 (d, J = 5.9 Hz, 2H), 7.39 (s, 1H), 7.20 (d, J = 5.9 Hz, 2H), 5.22 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.84 (s, 3H), 3.58 - 3.49 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H), 0.87 - 0.75 (m, 2H), -0.13 (s, 9H). **¹³C-NMR** (101 MHz, CDCl_3) δ = 165.1, 162.6, 161.3, 150.1, 142.0, 136.6, 123.7, 114.4, 111.4, 76.4, 67.9, 62.3, 59.3, 18.2, 14.2, -1.3. **HRMS-ESI** calcd for $\text{C}_{20}\text{H}_{29}\text{N}_2\text{O}_5\text{Si}^+$: 405.1840, found 405.1830.

2-Methoxy-4-(pyridin-3-yl)phenol 13: The reaction was carried out according



general to general procedure 2.1. using the following amounts:

3-bromopyridine (100 mg, 633 μ mol, 1.0 eq.), Pd(PPh₃)₄ (73 mg, 63 μ mol, 0.1 eq.), K₂CO₃ (262 mg, 1.90 mmol, 3.0 eq.), 2-


methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (237 mg, 0.96 mmol, 1.5 eq.). The reaction mixture was diluted with EtOAc, washed twice with brine, dried over sodium sulfate and purified by flash chromatography (SiO₂, Et₂O). The obtained oil was dissolved in DCM and was then extracted three times with sat. aq. sodium bicarbonate solution to remove residual boronic ester. The organic layer was then dried over sodium sulfate and the crude material was further purified by recrystallisation in Et₂O to give a colourless solid (89 mg, 442 μ mol, 70%). **M.p.** : 148-150°C, **R_f** = 0.23 (SiO₂, pentane/EtOAc 4:1). **FTIR** (neat): $\tilde{\nu}$ = 2991, 2943, 1590, 1518, 1465, 1434, 1399, 1366, 1308, 1216, 1185, 1125, 891, 855, 786, 709 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 8.81 (d, *J* = 2.0 Hz, 1H), 8.55 (dd, *J* = 4.8, 1.6 Hz, 1H), 7.85 - 7.80 (m, 1H), 7.34 (dd, *J* = 7.9, 4.8 Hz, 1H), 7.12 - 7.00 (m, 3H), 6.02 (s, 1H), 3.97 (s, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 148.03, 147.89, 147.11, 146.08, 136.69, 134.04, 130.12, 123.51, 120.36, 115.12, 109.61, 56.06. **HRMS-ESI** calcd for C₁₂H₁₂NO₂⁺: 202.0863, found 202.0863.

2.2 General Procedure for the Deprotection of O-SEM Protected Pyridones

To a stirred solution of *O*-SEM protected pyridone (1.0 eq., 0.05 M in DCM) at rt was added TFA (1.0 eq.) and the reaction was monitored by TLC. Further aliquots of TFA (0.2 eq.) were added until TLC indicated complete conversion. The solvent was removed *in vacuo* and the residue was dissolved in a minimum amount of DCM. To the resulting solution pentane was added until precipitation was observed. The slurry was stored at 4°C over night. The precipitate was collected and washed with cold pentane. Precipitation was repeated if required.

Ethyl 4-methoxy-5-(4-((4-methoxybenzyl)oxy)phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 10⁽⁵⁾: The compound was prepared according to literature procedures. All analytical data was in full agreement with the previously published values.

Ethyl 5-(4-((*tert*-butoxycarbonyl)amino)phenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate 12e: The reaction was carried out according to



general procedure 2.2. using the following amounts:

8b (280 mg, 540 μmol , 1.0 eq.). The product was obtained as a colourless solid (160 mg, 412 μmol , 76 %). **M.p.** : 230-233°C, R_f = 0.25 (SiO_2 , DCM/MeOH

15:1). **FTIR** (neat): $\tilde{\nu}$ = 3260, 2979, 1734, 1717, 1715, 1615, 1588, 1533, 1525, 1445, 1391, 1363, 1298, 1235, 1150, 1076, 893, 830 cm^{-1} . **$^1\text{H-NMR}$** (400 MHz, $(\text{CD}_3)_2\text{SO}$) δ = 11.90 (s, 1H), 9.41 (s, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.36 (s, 1H), 7.27 (d, J = 8.6 Hz, 2H), 4.24 (q, J = 7.1 Hz, 2H), 3.57 (s, 1H), 1.48 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H). **$^{13}\text{C-NMR}$** (101 MHz, $(\text{CD}_3)_2\text{SO}$) δ = 165.3, 163.6, 160.7, 152.8, 138.8, 135.6, 129.1, 127.3, 118.0, 114.3, 112.7, 79.1, 61.0, 59.4, 28.1, 13.9. **HRMS-ESI** calcd for $\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}_6^+$: 389.1713, found 389.1707.





Figure 1 X-ray structure of Ethyl 5-(4-((*tert*-butoxycarbonyl)amino)phenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate, CCDC 888459.

4-(5-(ethoxycarbonyl)-4-methoxy-6-oxo-1,6-dihydropyridin-3-yl)benzenaminium

2,2,2-trifluoroacetate 12f: 12e (86 mg, 0.22 μmol , 1.0 eq.) was dissolved in TFA (2



mL, 50% in DCM) at rt and monitored by TLC.

After 3h DCM (5 mL) was added and the solvents were removed *in vacuo*. The crude material was dissolved in DCM and a minimum amount of MeOH

and then pentane was added until precipitation began. The mixture was stored in the

fridge over night, filtered, dried *in vacuo* which gave **12f** as a colourless crystals (83

mg, 0.21 μmol , 93 %). **M.p.** : 168-171°C, **R_f** = 0.15 (SiO₂, DCM/MeOH 9:1). **FTIR**

(neat): $\tilde{\nu}$ = 2880, 1728, 1678, 1635, 1515, 1470, 1396, 1304, 1169, 1120, 1078,

1012, 832, 795, 709 cm^{-1} . **¹H-NMR** (400 MHz, (CD₃)₂SO) δ = 7.38 (s, 1H), 7.32 (d, *J*


= 8.5 Hz, 2H), 7.06 (d, *J* = 8.4 Hz, 2H), 4.24 (q, *J* = 7.1 Hz, 2H), 3.59 (s, 3H), 1.26 (t,

J = 7.1 Hz, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 186.3, 165.4, 163.5, 160.8 135.7,

129.9, 119.4, 119.3, 114.1, 112.4, 61.1, 59.3, 13.9. **¹⁹F-NMR** (367 MHz, (CD₃)₂SO) δ

= -74.0. **HRMS-ESI** calcd for C₁₅H₁₇N₂O₄⁺: 289.1188, found 289.1183.

For the biological assays, a portion of **12f** was dissolved in EtOAc and extracted two



times with NaOH (1M). The aqueous layer was extracted

three times with DCM and the combined organic layers

were dried over sodium sulfate and the solvent removed


in vacuo to give the free base as an off white solid. No ¹⁹F

signal was observed in the fluorine NMR (see attached spectrum). **¹H NMR** (400

MHz, CDCl₃) δ = 7.32 (s, 1H), 7.14 (d, *J* = 8.4 Hz, 2H), 6.71 (d, *J* = 8.4 Hz, 2H), 4.41

(q, *J* = 7.1 Hz, 2H), 3.69 (s, 3H), 1.38 (t, *J* = 7.1 Hz, 3H).

Ethyl 4-methoxy-2-oxo-5-phenyl-1,2-dihydropyridine-3-carboxylate 12a: The




reaction was carried out according to general procedure 2.2. using the following amounts: **8e** (70 mg, 0.17 mmol, 1.0 eq.).

The product was obtained as a colourless solid (31 mg, 0.11 mmol, 65 %). **M.p.** : 146-148°C, **R_f** = 0.48 (SiO₂,


DCM/MeOH 15:1). **FTIR** (neat): $\tilde{\nu}$ = 2959, 2921, 2851, 1709, 2362, 1724, 1633, 1546, 1461, 1390, 1292, 1239, 1187, 1075, 1015, 988, 943, 880, 757, 701 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 13.37 (s, 1H), 7.49 -7.30 (m, 6H), 4.42 (q, *J* = 7.1 Hz, 2H), 3.70 (s, 3H), 1.38 (t, *J* = 7.1 Hz, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.8, 165.5, 164.1 136.1, 133.8, 129.1, 128.7, 127.9, 117.4, 112.5, 62.0, 59.8, 14.3. **HRMS-ESI** calcd for C₁₅H₁₆FNO₄⁺: 274.1074, found 274.1069.

Ethyl 5-(4-fluorophenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate




12b: The reaction was carried out according to general procedure 2.2. using the following amounts: **8d** (70 mg, 83 μmol , 1.0 eq.). The product was obtained as a colourless solid (13 mg, 45 μmol , 54 %). **M.p.** : 158-159°C, **R_f** = 0.51 (SiO₂, DCM/MeOH 15:1). **FTIR** (neat): $\tilde{\nu}$ = 2922, 2853, 2362, 1725, 1642, 1512, 1468, 1390, 1301, 1235, 1195, 1161, 1077, 838 cm^{-1} . **¹H-NMR** (400 MHz, CDCl₃) δ = 13.31 (s, 1H), 7.39 (s, 1H), 7.32 (dd, J = 8.4, J = 5.5 Hz, 2H), 7.10 (dd, J = 8.6, J = 8.6 Hz, 2H), 4.42 (q, J = 7.1 Hz, 2H), 3.73 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.9, 164.5 (d, J = 247.4 Hz), 164.1, 161.4, 135.9, 130.8 (d, J = 8.1 Hz), 129.8, 129.7, 116.9, 115.7 (d, J = 21.6 Hz), 62.1, 59.7, 14.3. **¹⁹F-NMR** (367 MHz, CDCl₃) δ = -114.3. **HRMS-ESI** calcd for C₁₅H₁₄FNO₄⁺: 292.0980, found 292.0974.

Ethyl 5-(4-(*tert*-butyl)phenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate 12c: The reaction was carried out according to general procedure 2.2.



using the following amounts: **8c** (69 mg, 0.15 mmol, 1.0 eq.). The product was obtained as a colourless solid (40 mg, 0.12 mmol, 81 %). **M.p.** : 240-241°C, **R_f** = 0.46 (SiO₂, DCM/MeOH 15:1). **FTIR** (neat): $\tilde{\nu}$ = 2962, 2918, 1851, 1722, 1633, 1545, 1472, 1388, 1293, 1242, 1197, 990, 884, 932, 765, 669, 611 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 13.42 (s, 1H), 7.41 (s, 1H), 7.41 (d, *J* = 8.3 Hz, 2H), 7.30 (d, *J* = 8.3 Hz, 2H), 4.42 (q, *J* = 7.1 Hz, 2H), 3.72 (s, 3H), 1.39 (t, *J* = 7.1 Hz, 4H), 1.34 (s, 9H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 165.5, 164.0, 160.0, 150.8, 135.9, 130.8, 128.6, 125.6, 117.1, 112.4, 62.0, 59.8, 34.7, 31.4, 14.2. **HRMS-ESI** calcd for C₁₉H₂₄NO₄⁺: 330.1700, found 330.1696.


5'-(ethoxycarbonyl)-4'-methoxy-6'-oxo-1',6'-dihydro-[3,3'-bipyridin]-1-ium 2,2,2-trifluoroacetate 12h: The reaction was carried out according to general procedure



2.2. using the following amounts: **8f** (79 mg, 0.20 mmol, 1.0 eq.). The crude was dissolved in DCM and extracted three times with saturated Na₂CO₃, dried over sodium sulfate to give the product as a yellow oil (34 mg, 0.12 mmol, 63%). **R_f**

= 0.36 (SiO₂, DCM/MeOH 10:1 + 0.1% TEA). **FTIR** (neat): $\tilde{\nu}$ = 2962, 2918, 1851, 1722, 1633, 1545, 1472, 1388, 1293, 1242, 1197, 990, 884, 932, 765, 669, 611 cm⁻¹. **¹H-NMR** (400 MHz, CD₂Cl₂) δ = 10.90 (s, 1H), 8.85 (s, 1H), 8.72 (m, 1H), 8.19 (m, 1H), 7.73 (m, 1H), 7.59 (s, 1H), 4.35 (q, *J* = 7.0 Hz, 1H,), 3.87 (s, 1H), 1.34 (t, *J* = 7.1 Hz, 1H,). **¹³C-NMR** (101 MHz, CD₂Cl₂) δ = 166.3, 164.8, 164.6, 150.1, 149.2, 134.0, 130.5, 123.7, 114.1, 112.0, 62.5, 59.9, 30.2, 14.4. **HRMS-ESI** calcd for C₁₄H₁₅N₂O₄⁺: 275.1026, found 275.1024.

Ethyl 5-(4-hydroxyphenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate




11a: The reaction was carried out according to general procedure 2.2. using the following amounts: **10** (24 mg, 59 μmol , 1.0 eq.). The product was obtained as a colourless solid (17 mg, 59 μmol , quant.). **M.p.** : 234-237°C, R_f = 0.31 (SiO₂, DCM/MeOH 15:1). **FTIR** (neat): $\tilde{\nu}$ = 3269, 2942, 2852, 1724, 1608, 1512, 1464, 1393, 1304, 1233, 1195, 1176, 1060, 962, 892, 842, 704 cm^{-1} . **¹H-NMR** (500 MHz, CD₃OD) δ = 7.35 (s, 1H), 7.22 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 3.65 (s, 3H) 1.36 (t, J = 7.1 Hz, 3H). **¹³C-NMR** (126 MHz, CD₃OD) δ = 167.3, 163.5, 158.6, 136.3, 131.2, 125.9, 119.4, 118.8, 116.5, 114.5, 62.7, 60.4, 14.3. **HRMS-ESI** calcd for C₁₅H₁₆NO₅⁺: 290.1023, found 290.1018.

2.3 General Procedure for the Deprotection of *N*-SEM Protected Pyridones with TBAF

To a solution of *N*-SEM protected pyridone (1.0 eq., 1 mL dry THF per 10 mg pyridone) under an argon atmosphere was added TBAF (1.2 eq., 1.0 M in THF). The reaction mixture was heated to 60°C and monitored by TLC. Upon completion, the reaction mixture was then allowed to cool to rt and the solvent was removed *in vacuo*. The crude product was purified by gradient flash chromatography.


Ethyl 5-(4-hydroxy-3-methoxyphenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-



carboxylate 12d: The reaction was carried out according to general procedure 2.3 using the following amounts: **8g** (44 mg, 0.98 mmol, 1.0 eq.) and TBAF (0.12 mL, 1M in THF, 0.12 mmol, 1.2 eq.). The crude product was purified by flash chromatography (SiO₂,

DCM/MeOH 15:1) to give a colourless solid (22 mg, 0.69 mmol, 70%). **M.p.** : 77-78°C, **R_f** = 0.17 (SiO₂, DCM/MeOH 12:1). **FTIR** (neat): $\tilde{\nu}$ = 3341, 3130, 2963, 2845, 1730, 1625, 1513, 1467, 1388, 1303, 1253, 1194, 1075, 1029, 884, 823, 700 cm⁻¹. **¹H-NMR** (500 MHz, CDCl₃) δ = 13.27 (s, 1H), 7.38 (s, 1H), 6.87 (d, *J* = 8.1 Hz, 1H) 6.82 - 6.78 (m, 2H), 5.67 (s, 1H), 4.42 (q, *J* = 7.1 Hz, 2H), 3.90 (s, 3H), 3.70 (s, 3H), 1.39 (t, *J* = 7.1 Hz, 3H). **¹³C-NMR** (126 MHz, CDCl₃) δ = 165.9, 165.6, 163.9, 146.6, 145.6, 135.8, 125.7, 122.11, 117.4, 114.7, 113.0, 111.7, 62.1, 59.9, 56.2, 14.3. **HRMS-ESI** calcd for C₁₆H₁₆NO₆⁺: 320.1134, found 320.1129.

Ethyl 4-methoxy-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carboxylate 12g: The



reaction was carried out according to general procedure 2.3 using the following amounts: **8h** (23 mg, 57 μmol , 1.0 eq.) and TBAF (68 μL , 1M in THF, 68 μmol , 1.2 eq.). The crude

product was purified by flash chromatography (SiO_2 ,

DCM/MeOH 12:1 + 0.1% TEA) to give a yellow oil (10 mg, 37 μmol , 64%). R_f =

0.22 (SiO_2 , DCM/MeOH 12:1 + 0.1% TEA). **FTIR** (neat): $\tilde{\nu}$ = 2922, 2853, 1724,

1631, 1466, 1399, 1260, 1079, 1022, 628 cm^{-1} . **$^1\text{H-NMR}$** (400 MHz, CDCl_3) δ =

13.33 (s, 1H), 8.61 (d, J = 5.9 Hz, 2H), 7.51 (s, 1H), 7.40 (d, J = 5.9 Hz, 2H), 3.80 (s,


H), 4.37 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). **$^{13}\text{C-NMR}$** (101 MHz, CDCl_3) δ

= 165.7, 164.4, 164.2, 150.1, 142.0, 136.3, 123.6, 114.7, 111.9, 62.3, 59.7, 14.2.

HRMS-ESI calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_4^+$: 275.1110, found 275.1026.

Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate

9a: To **8a** (230 mg, 0.53 mmol, 1.0 eq.) in DMF (1 mL) TBAF (1.60 mL, 1M in THF, 1.06 mmol, 1.2 eq.) was added. The mixture was stirred



for 6h at 60°C. The solvents were removed *in vacuo* and the crude material was dissolved in DCM. Upon slow addition of *n*-hexane, the target compound **9a**

precipitated from the solution. The colorless solid was filtered and washed with DCM/hexane (1:1; 5 mL), yielding **9a** (87.2 mg, 0.29 mmol, 54%). **M.p.** : 186-188°C.

R_f = 0.26 (SiO₂, DCM/MeOH 15:1). **FTIR** (neat): $\tilde{\nu}$ = 2981, 1728, 1637, 1514, 1465, 1393, 1300, 1245, 1181, 1076, 784 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 13.43 (s, 1H), 7.38 (s, 1H), 7.31 – 7.25 (m, 2H), 6.92 (dd, *J* = 9.2, 2.4 Hz, 2H), 4.41 (q, *J* = 7.1 Hz, 2H), 3.83 (s, 3H), 3.69 (s, 3H), 1.38 (t, *J* = 7.1 Hz, 3H). **¹³C-NMR** (101 MHz, CDCl₃) δ = 166.2, 165.8, 164.3, 159.7, 136.1, 130.5, 126.4, 117.3, 114.4, 113.0, 62.2, 60.1, 55.7, 14.6. **HRMS-ESI** calcd for C₁₆H₁₈NO₅⁺: 304.1179, found 304.1175.




Figure 5.3. X-ray structure of **Polymorph A** CCDC 888460 of Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate.




Figure 5.3. X-ray structure of **Polymorph B** CCDC 888461 of Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate.





Figure 5.3. Overlay of the X-ray structures of **Polymorph A** (CCDC 888460) and **Polymorph B** (CCDC 888461) of Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate. The ethyl-carboxylate groups on the left site are rotated at about 180°.


Ethyl 4-methoxy-5-(4-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 9c: To a solution of ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-



dihydropyridine-3-carboxylate **9a** (21 mg, 69 μ mol, 1.0 equiv.) in CH_3CN (2 mL) was added potassium carbonate (19 mg, 0.14 mmol, 2.0 equiv.) followed by methyl iodide (49 mg, 0.34 mmol, 5.0 equiv.) . The


mixture was stirred 4 hours at 50 $^{\circ}\text{C}$. The solvents were removed *in vacuo* and the crude material was dissolved in diethyl ether (15 mL). After aqueous extraction (3x5 mL), the organic layer was dried over sodium sulfate and the solvents removed *in vacuo*. Flash chromatography with DCM/MeOH (15:1) yielded **9c** (17 mg, 54 μ mol, 77%) as a colorless oil. R_f = 0.40 (SiO_2 , DCM/MeOH 20:1). **FTIR** (neat): $\tilde{\nu}$ = 2957, 1725, 1648, 1512, 1513, 1463, 1397, 1358, 1305, 1246, 1207, 1152, 1092, 1023, 836, 631 cm^{-1} . **$^1\text{H-NMR}$** (400 MHz, CDCl_3) δ = 7.28 – 7.24 (m, 2H), 7.20 (s, 1H), 6.94 – 6.89 (m, 2H), 4.41 (q, J = 7.1 Hz, 2H), 3.83 (s, 3H), 3.69 (s, 3H), 3.52 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). **$^{13}\text{C-NMR}$** (101 MHz, CDCl_3) δ = 166.1, 163.6, 161.2, 159.4, 138.3, 130.3, 126.1, 116.2, 114.1, 112.5, 62.0, 59.5, 55.4, 37.2, 14.3. **HRMS-ESI** calc. for $\text{C}_{17}\text{H}_{20}\text{NO}_5^+$: 318.1336 found: 318.1342.

Ethyl 5-(4-hydroxyphenyl)-4-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 11c: A 10 mL round bottom flask was charged with flame dried K₂CO₃



(17 mg, 0.12 mmol, 2.0 equiv) and Ethyl 4-methoxy-5-(4-((4-methoxybenzyl)oxy)phenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate **10^{xy}** (25 mg, 60 μmol, 1.0 equiv.). The solids were suspended in Acetonitrile (2 mL) and MeI (43 mg, 0.30 mmol, 5.0 equiv) was added. The reaction mixture was heated to 35°C over night, after which TLC analysis (SiO₂, DCM/MeOH 20:1, R_f = 0.50) indicated complete formation of the product. The solvents were removed *in vacuo*, the residue was taken up in Et₂O (10 mL) and the organic layer was extracted with water (3x5 mL). The layers were separated, and the organic layer was dried over sodium sulfate, filtered and the solvents removed *in vacuo*. The residue was dissolved in DCM containing 2.5% TFA v/v (2 mL). The mixture was stirred 10 minutes at room temperature. The mixture was diluted with a saturated solution of NaHCO₃ (10 mL) and extracted with DCM (3x5 mL). The combined organic layers were dried over sodium sulfate and the solvents removed *in vacuo*. Flash chromatography with DCM/MeOH (15:1) yielded **11c** (17 mg, 50 μmol, 83%) as a colorless oil. R_f = 0.50 (SiO₂, DCM/MeOH 15:1). **FTIR** (neat): $\tilde{\nu}$ = 3171, 2950, 1723, 1642, 1577, 1513, 1400, 1269, 1210, 1152, 1090, 1017, 838, 709 cm⁻¹. **¹H-NMR** (400 MHz, MeOD) δ = 7.62 (s, 1H), 7.27 – 7.19 (m, 2H), 6.86 – 6.78 (m, 2H), 4.35 (q, *J* = 7.1 Hz, 2H), 3.63 (s, 3H), 3.55 (s, 3H), 1.36 (t, *J* = 7.1 Hz, 3H). **¹³C-NMR** (101 MHz, MeOD) δ = 167.3, 165.9, 162.7, 158.6, 141.0, 131.3, 125.8, 118.6, 116.4, 114.2, 62.9, 60.5, 37.5, 14.4. **HRMS-ESI** calc. for: C₁₆H₁₈NO₅⁺: 304.1185 found: 304.1192.


Ethyl 4-hydroxy-5-(4-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 9d:



4-methoxy-5-(4-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate **9c** (14 mg, 0.04 mmol, 1.0 equiv.) was dissolved in THF (1.5 mL). Freshly crystallized LiI (12 mg, 0.09 mmol, 2.0 equiv.) and pyridinium chloride (10 mg, 0.09 mmol, 2.0 equiv.) were added. The reaction mixture was stirred at 60 °C for 16 hours. The solvents were removed *in vacuo* and the residue taken up in ethyl acetate (10 mL). The organic layer was washed with brine (2x 5 mL). The organic layer was dried over sodium sulfate and the solvents removed *in vacuo*. Semipreparative HPLC purification (RP-18, gradient acetonitrile/water) yielded **9d** (3 mg, 0.01 mmol, 24%) as a colorless foam after lyophilization. R_f = 0.45 (SiO₂, DCM/MeOH 10:1). **FTIR** (neat): $\tilde{\nu}$ = 2926, 2361, 1659, 1538, 1412, 1325, 1245, 1178, 1099, 1032, 834, 769, 680, 630 cm⁻¹. **¹H-NMR** (500 MHz, CDCl₃) δ = 13.94 (s, 1H), 7.41 (s, 1H), 7.35 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 8.6 Hz, 2H), 4.47 (q, J = 7.1 Hz, 2H), 3.84 (s, 3H), 3.53 (s, 3H), 1.47 (t, J = 7.1 Hz, 3H). **¹³C-NMR** (125 MHz, CDCl₃) δ = 173.1, 172.4, 160.0, 159.4, 142.2, 130.4, 125.0, 114.1, 113.4, 98.7, 62.1, 55.4, 37.6, 14.2. **HRMS-ESI** calc. for: C₁₆H₁₈NO₅⁺: 304.1185 found: 304.1173.

Ethyl 4-hydroxy-5-(4-hydroxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate

11b: Ethyl 5-(4-hydroxyphenyl)-4-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-3-




carboxylate **11a** (20 mg, 0.07 mmol, 1.0 equiv.) was dissolved in THF (2 mL). Freshly crystallized LiI (19 mg, 0.14 mmol, 2.0 equiv.) and pyridinium chloride (16 mg, 0.14 mmol, 2.0 equiv.) were added. The reaction mixture

was stirred at 60 °C for 16 hours. The solvents were removed *in vacuo* and the residue was purified by flash chromatography with DCM/MeOH 9:1 to 5:1, yielding **11b** (18 mg, 0.07 mmol, 95%) as a colorless sticky solid. R_f = 0.48 (SiO₂, DCM/MeOH 9:1).

FTIR (neat): $\tilde{\nu}$ = 3375, 2361, 1672, 1434, 1201, 1136, 1018, 953, 802 cm⁻¹. **¹H-NMR** (400 MHz, DMSO-d₆) δ = 13.62 (s, 1H), 11.62 (s, 1H), 9.61 (s, 1H), 7.47 (s, 1H), 7.30-7.18 (m, 2H), 6.84-6.74 (m, 2H), 4.37-4.27 (m, 2H), 1.28 (t, J = 7.0 Hz, 3H). **¹³C-NMR** (101 MHz, DMSO-d₆) δ = 172.6, 172.0, 159.2, 156.9, 139.6, 130.2, 115.1, 98.4, 61.3, 48.7, 14.2. The quarternary carbon atom at the C (3) position of the pyridone ring could not be observed. **HRMS-ESI** calc. for: C₁₄H₁₄NO₅⁺: 276.0866 found: 276.0865.

Ethyl 4-hydroxy-5-(4-methoxyphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 9b:



3-carboxylate **9a** (8.0 mg, 0.026 mmol, 1.0 equiv.) was dissolved in degassed THF (1.5 mL). Freshly crystallized LiI (9.8 mg, 0.052 mmol, 2.0 equiv.) and pyridinium chloride (6.1 mg, 0.052 mmol, 2.0 equiv.) were added. The reaction mixture was stirred at 60 °C for 24 hours. The solvents were removed *in vacuo* and the residue taken up in ethyl acetate (10 mL). The organic layer was washed with brine (5 mL) and water (5 mL). The organic layer was dried over sodium sulfate and the solvents removed *in vacuo*. Flash chromatography (SiO₂, DCM:MeOH 30:1) gave the product as a colourless oil. R_f = 0.15 (SiO₂, DCM/MeOH 30:1). **FTIR** (neat): $\tilde{\nu}$ = 2923, 2362, 1678, 1459, 1408, 1250, 1203, 1076, 1032, 839, 765, 630 cm⁻¹. **¹H-NMR** (400 MHz, CDCl₃) δ = 14.10 (s, 1H), 11.85 (s, 1H), 7.47 (s, 1H), 7.36 (d, J = 8.7 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 4.50 (q, J = 7.1 Hz, 1H), 3.84 (s, 1H), 1.46 (t, J = 7.2 Hz, 2H). **¹³C-NMR** (125 MHz, CDCl₃) δ = 174.2, 172.4, 162.2, 159.3, 138.31, 130.2, 130.1, 124.9, 114.4, 113.9, 62.3, 50.1, 14.1. **HRMS-ESI** calc. for: C₁₅H₁₅NO₅⁺: 289.0950 found: 289.0950.

3. Experimental Conditions of the PC-12 Assay

All experiments were conducted under strictly sterile conditions. Dulbecco's modified eagle medium (DMEM), collagen coated 24-well plates (Becton Dickinson Labware, UK), NGF-7S from murine submaxillary gland, penicillin-streptomycin and Giemsa stain were purchased from Aldrich. TrypLE, horse serum and fetal bovine serum (heat inactivated) were obtained from Invitrogen. PC-12 cells were purchased from ATCC-LGC. The PC-12 assay has been extensively described elsewhere.⁶ Briefly, PC-12 cells were cultured in DMEM (10% horse serum, 5% fetal bovine serum, heat inactivated, 200 U/mL Penicillin, 200 mg/mL Streptomycin, 0.005 % β -mercapto ethanol, high glucose + L-Glutamine). Cell aggregates were separated by passage through a 21-gauge needle. Assays were conducted in collagene coated 24-well-plates. Cell suspensions from primary culture (10^5 cells/mL) were preincubated 1 day and then 3 d incubated with the substances. On each plate separate blank measurements with DMSO (0.1%) and with 10 ng/mL NGF were conducted. All assays were performed in triplicate. After incubation cells were fixed with 5% PBS-buffered formaldehyde solution at 0 °C for 1h, stained with giemsa stain (5 min at rt) and washed with PBS three times. Cells from three to five randomly chosen areas were counted and the percentage of neurite positive cells determined (>500 cells per compound). Processes with a length equivalent to one or more diameters of the cell body were regarded as neurites. Significance of the results was examined by ANOVA (Dunnett's posttest) through comparison with blank experiments. ERK-Inhibitor (PD 98059) was obtained from Invitrogen and used as described.

⁶ a) I. Dikic, J. Schlessinger, I. Lax, *Curr. Biol.* **1994**, *4*, 702-708, b) H. J. Jessen, D. Barbaras, M. Hamburger, K. Gademann, *Org. Lett.* **2009**, *11*, 3446-3449, c) Y. Obara, T. Aoki, M. Kusano, Y. Ohizumi, *J. Pharmac. Exp. Ther.* **2002**, *301*, 803-811.

4. X-ray Structure Parameters

X-ray parameters of Ethyl 5-(4-((*tert*-butoxycarbonyl)amino)phenyl)-4-methoxy-2-oxo-1,2-dihydropyridine-3-carboxylate **19**, CCDC 888459:

formula	C ₂₀ H ₂₄ N ₂ O ₆
formula weight	388.42
Z, calculated density	4, 1.310 Mg · m ⁻³
F(000)	824
description and size of crystal	colourless plate, 0.03·0.13·0.22 mm ³
absorption coefficient	0.097 mm ⁻¹
min/max transmission	0.99 / 1.00
temperature	123K
radiation(wavelength)	Mo K _α (λ = 0.71073 Å)
Crystal system, space group	monoclinic, P 2 ₁ /n
a	12.3996(3) Å
b	8.7715(2) Å
c	18.6699(4) Å
α	90°
β	104.0880(10)°
γ	90°
V	1969.52(8) Å ³
min/max Θ	2.249° / 36.364°
number of collected reflections	55114
number of independent reflections	9575 (merging r = 0.059)
number of observed reflections	4981 (I>2.0σ(I))
number of refined parameters	253
r	0.0430
rW	0.1019
goodness of fit	1.0758


X-ray parameters of Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 9a, Polymorph A CCDC 888460:


formula	C ₁₆ H ₁₇ NO ₅
formula weight	303.31
Z, calculated density	2, 1.377 Mg · m ⁻³
F(000)	320
description and size of crystal	colourless block, 0.16·0.21·0.35 mm ³
absorption coefficient	0.103 mm ⁻¹
min/max transmission	0.98 / 0.98
temperature	123K
radiation(wavelength)	Mo K _α (λ = 0.71073 Å)
Crystal system, space group	triclinic, P -1
a	7.2983(2) Å
b	9.2081(3) Å
c	12.3051(5) Å
α	107.988(2)°
β	96.327(2)°
γ	107.4030(10)°
V	731.59(5) Å ³
min/max Θ	1.785° / 32.577°
number of collected reflections	18834
number of independent reflections	5257 (merging r = 0.028)
number of observed reflections	4090 (I>2.0σ(I))
number of refined parameters	199
r	0.0406
rW	0.0587
goodness of fit	1.0968

X-ray parameters of Ethyl 4-methoxy-5-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 9a, Polymorph B CCDC 888461:


formula	C ₁₆ H ₁₇ NO ₅
formula weight	303.31
Z, calculated density	4, 1.371 Mg · m ⁻³
F(000)	640
description and size of crystal	colourless block, 0.04 · 0.05 · 0.19 mm ³
absorption coefficient	0.103 mm ⁻¹
min/max transmission	0.99 / 1.00
temperature	123K
radiation(wavelength)	Mo K _α (λ = 0.71073 Å)
Crystal system, space group	monoclinic, P 21/c
a	11.3216(5) Å
b	7.0251(3) Å
c	18.4969(8) Å
α	90°
β	92.747(3)°
γ	90°
V	1469.47(11) Å ³
min/max Θ	1.801° / 30.999°
number of collected reflections	28905
number of independent reflections	4690 (merging r = 0.097)
number of observed reflections	2116 (I>2.0σ(I))
number of refined parameters	199
r	0.0517
rW	0.1295
goodness of fit	1.0906

5. NMR Spectra







Supporting Information




Supporting Information




Supporting Information







Supporting Information




Supporting Information









Supporting Information









Supporting Information




Supporting Information





Supporting Information




Supporting Information











hj-514
User/Group Henning Jensen/Gademann
hj-514
Proton MeOH uicon jessen 12

Supporting Information





Supporting Information




Supporting Information

HJ-511
User/Group Henning Jessen/Gademann
HJ-511
_C13cpd CDCl3 uicon jessen 9





Supporting Information




hj-441
User/Group Henning Jessen/Gademann
hj-441
_Proton CDCl3 uicon jessen 2

Supporting Information







Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information










Supporting Information






Supporting Information







Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information





Supporting Information




Supporting Information









Supporting Information




Supporting Information




Supporting Information






Supporting Information





Supporting Information





Phenomenex Gemini



6. HPLC Traces

5 μ C18 110 A, 50 x 4.6 mm





Phenomenex Gemini
Phenomenex Gemini





Phenomenex Gemini



5 μ C18 110 A, 250 x 4.6 mm

5-100% MeCN/H₂O in 30 min,
then 5 min 100% MeCN, 1 mL/min

